The Wall St. Journal did an interesting piece on the New England Journal of Medicine’s apparent flexibility with the facts regarding the Vioxx study.
I used to work for a scientific abstracts journal, and much later, for a pharmaceutical consulting firm. Personally, I have very little faith in the integrity of the drug-approval process.
I was surprised to learn in this piece that the NEJM makes $88 million a year. When that kind of money comes into play, corruption is almost inevitable.







The link goes to an Actblue contribution page instead of a Wall Street Journal article.